» Articles » PMID: 35126725

SLAMF6/Ly108 Promotes the Development of Hepatocellular Carcinoma Via Facilitating Macrophage M2 Polarization

Overview
Journal Oncol Lett
Specialty Oncology
Date 2022 Feb 7
PMID 35126725
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) are capable of worsening hepatocellular carcinoma (HCC) prognosis by accelerating tumor growth and progression. Signaling lymphocyte activation molecule family member 6 (SLAMF6; Ly108 in mice) is an immune regulator that is involved in numerous diseases. However, whether SLAMF6 might affect macrophage function in HCC has not yet been reported. Therefore, the present study aimed to determine the relationship between SLAMF6 expression on macrophages and HCC progression. In the present study, the expression of SLAMF6 in human blood samples and mice was analyzed by flow cytometry. Furthermore, macrophage-related polarization markers were detected via reverse transcription quantitative PCR. Clonogenic formation and Transwell assay were performed to determine the proliferation, migration and invasion of HCC cells. In addition, a murine HCC model was established to detect the function of SLAMF6 . The results demonstrated that SLAMF6 expression was increased in CD14 cells obtained from patients with HCC. It was also determined that this increase was associated with a positive hepatitis B virus DNA status and high levels of α-fetoprotein. Polarized TAMs from THP-1 cells, murine peritoneal macrophages and murine bone marrow-derived macrophages all exhibited higher levels of SLAMF6 compared with M1 cells. Furthermore, an increased expression of Ly108 was detected in macrophages obtained from mice tumor tissues, indicating that the tumor microenvironment may promote Ly108 expression and macrophage M2 polarization. Ly108 small interfering RNA was applied to macrophages, which resulted in the suppression of M2 polarization. Ly108-silenced macrophages attenuated HCC cell migration and invasion and prevented tumor growth by inhibiting the nuclear factor-κB pathway. Altogether, the results from the present study suggested that SLAMF6/Ly108 was upregulated in TAMs, which may in turn accelerate the development of HCC.

Citing Articles

SLAM family-mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies.

Kwantwi L Clin Transl Oncol. 2024; .

PMID: 39212911 DOI: 10.1007/s12094-024-03675-2.


Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.

Li D, Zhang T, Guo Y, Bi C, Liu M, Wang G Cell Death Dis. 2024; 15(7):498.

PMID: 38997297 PMC: 11245522. DOI: 10.1038/s41419-024-06888-z.


Generation of Myeloid-Derived Suppressor Cells Mediated by MicroRNA-125a-5p in Melanoma.

Lasser S, Ozbay Kurt F, Fritz L, Gutzeit N, de la Torre C, Altevogt P Int J Mol Sci. 2024; 25(12).

PMID: 38928399 PMC: 11203613. DOI: 10.3390/ijms25126693.


Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior.

Siciliano M, Bertolazzi G, Morello G, Tornambe S, Del Corvo M, Granai M Blood Adv. 2024; 8(16):4330-4343.

PMID: 38861355 PMC: 11372814. DOI: 10.1182/bloodadvances.2023011506.


Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors.

Gunes M, Rosen S, Shachar I, Gunes E Front Immunol. 2024; 15:1297473.

PMID: 38476238 PMC: 10927787. DOI: 10.3389/fimmu.2024.1297473.


References
1.
Yigit B, Halibozek P, Chen S, OKeeffe M, Arnason J, Avigan D . A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget. 2016; 7(18):26346-60. PMC: 5041984. DOI: 10.18632/oncotarget.8378. View

2.
. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

3.
Wang N, Keszei M, Halibozek P, Yigit B, Engel P, Terhorst C . Slamf6 negatively regulates autoimmunity. Clin Immunol. 2016; 173:19-26. PMC: 5206809. DOI: 10.1016/j.clim.2016.06.009. View

4.
Wynn T, Vannella K . Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016; 44(3):450-462. PMC: 4794754. DOI: 10.1016/j.immuni.2016.02.015. View

5.
Marcq I, Nyga R, Cartier F, Amrathlal R, Ossart C, Ouled-Haddou H . Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. PLoS One. 2013; 8(12):e82918. PMC: 3869749. DOI: 10.1371/journal.pone.0082918. View